Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 317-323

  Jahnke, Kristoph ^a   Keilholz, Ulrich ^a   Lüftner, Diana ^a   Thiel, Eckhard ^a   Schmittel, Alexander ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Carboplatin; Chemotherapy; Non small cell lung cancer; Paclitaxel; Vinorelbine

Indexed keywords

CARBOPLATIN; PACLITAXEL; VINORELBINE DITARTRATE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 79851490471     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Cullen MH, Billingham LJ, Woodroffe CM et al: Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J Clin Oncol 17: 3188-3194, 1999. (Pubitemid 29470650)
2. Klastersky J, Sculier JP, Lacroix H et al: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 8: 1556-1562, 1990. (Pubitemid 20301187)
3. Bunn PA Jr. and Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4: 1087-1100, 1998.
4. Schiller JH, Harrington D, Belani CP et al: Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002.
5. Wolf M, Havemann K, Schneider P, Vogt-Moykopf I and Budach V: Nichtkleinzelliges Bronchialkarzinom. In: Kompendium Internistische Onkologie - Standards in Diagnostik und Therapie. Teil 2: Therapiekonzepte maligner Tumoren. Schmoll HJ, Höffken K and Possinger K (eds.). Heidelberg, Springer, pp. 3467-3584, 2006.
6. Therasse P, Arbuck SG, Eisenhauer EA et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
7. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E and Boukovinas J: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol 20: 3578-3585, 2002. (Pubitemid 34983216)
8. Tan EH, Szczesna A, Krzakowski M et al; GLOB 2 group: Randomized study of vinorelbine-gemcitabine versus vinorelbine-carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 49: 233-240, 2005.
9. Yoh K, Kubota K, Kakinuma R et al: Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy. Lung Cancer 58: 73-79, 2007. (Pubitemid 47379960)
10. Nakadate M, Yamazaki K, Konishi J et al: Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Anticancer Res 26(5B): 3767-3772, 2006. (Pubitemid 44701457)
11. Sumiyoshi H, Yamasaki M, Doi M et al: Carboplatin plus gemcitabine therapy versus carboplatin plus weekly paclitaxel therapy for advanced non-small cell lung cancer. Gan To Kagaku Ryoho 33: 773-777, 2006.
12. Zhang L, Zhang Y, Li N, Xu F, Pan ZK and Guan ZZ: Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC). Ai Zheng 23(11 Suppl): 1455-1458, 2004.
13. Akerley W, Safran H, Zaner K, Ready N, Mega T and Kennedy T: Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV non-small cell lung cancer. Cancer 107: 1050-1054, 2006. (Pubitemid 44291154)
14. Yamamoto N, Nakagawa K, Uejima H et al: West Japan Thoracic Oncology Group (WJTOG): Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104. Cancer 107: 599-605, 2006.
15. Georgoulias V, Papadakis E, Alexopoulos A et al: Greek Oncology Cooperative Group (GOCG) for Lung Cancer: Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: a randomised multicentre trial. Lancet 357(9267): 1478-1484, 2001. (Pubitemid 32488857)
16. Bajetta E, Chiara Stani S, De Candis D et al: Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial. Cancer 89: 763-768, 2000. (Pubitemid 30658574)
17. Lilenbaum R, Cano R, Schwartz M et al: Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: a phase II study. Cancer 88: 557-562, 2000. (Pubitemid 30056929)
18. Laack E, Mende T, Benk J et al: Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial. Eur J Cancer 37: 583-590, 2001. (Pubitemid 32261015)
19. Breathnach OS, Georgiadis MS, Schuler BS et al: Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer. Clin Cancer Res 6: 2670-2676, 2000. (Pubitemid 30482102)
20. Min YJ, Ahn JJ, Noh YJ et al: A less intensive combination of paclitaxel and carboplatin in advanced non-small cell lung cancer patients who have aged 60 years or more and has a poor performance status. Korean J Intern Med 19: 109-113, 2004. (Pubitemid 41237474)
21. Dongiovanni V, Addeo A, Berruti A et al: A phase II trial of weekly paclitaxel and gemcitabine in non-small cell lung cancer patients previously treated with platinum and vinorelbine. Anticancer Res 24: 2567-2572, 2004. (Pubitemid 39166349)
22. Katakami N, Sugiura T, Nogami T et al: Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908. Lung Cancer 43: 93-100, 2004. (Pubitemid 38096298)
23. Greco FA, Spigel DR, Kuzur ME et al: Paclitaxel/carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer 8: 483-487, 2007. (Pubitemid 47606357)
24. Kubota K, Watanabe K, Kunitoh H et al: Japanese Taxotere Lung Cancer Study Group: Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small cell lung cancer. J Clin Oncol 22: 254-261, 2004. (Pubitemid 41095089)
25. Scagliotti GV, De Marinis F, Rinaldi M et al: Italian Lung Cancer Project: Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 20: 4285-4291, 2002. (Pubitemid 35266288)
26. Lilenbaum RC, Chen CS, Chidiac T et al: Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small cell lung cancer. Ann Oncol 16: 97-101, 2005. (Pubitemid 40124485)
27. Rosell R, Gatzemeier U, Betticher DC et al: Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small cell lung cancer: a cooperative multinational trial. Ann Oncol 13: 1539-1549, 2002. (Pubitemid 35331451)
28. Yumuk PF, Turhal NS, Gumus M et al: Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer. BMC Cancer 5: 10, 2005.
29. Kelly K, Pan Z, Murphy J, Huffman DH and Bunn PA Jr.: A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res 3: 1117-1123, 1997. (Pubitemid 27319758)
30. Herbst RS, Khuri FR, Lu C et al: The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced non-small cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer 95: 340-353, 2002. (Pubitemid 34787601)
31. Hainsworth JD, Burris HA III, Billings FT III, Bradof JE, Baker M and Greco FA: Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network. Cancer 92: 2391-2398, 2001. (Pubitemid 33029084)
32. Nelli F, Naso G, De Pasquale Ceratti A et al: Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial. J Chemother 16: 392-399, 2004. (Pubitemid 39049891)
33. Brogden JM and Nevidjon B: Vinorelbine tartrate (Navelbine): drug profile and nursing implications of a new vinca alkaloid. Oncol Nurs Forum 22: 635-646, 1995.
34. Sakai H, Yoneda S, Tamura T et al: A phase II study of paclitaxel plus cisplatin for advanced non-small cell lung cancer in Japanese patients. Cancer Chemother Pharmacol 48: 499-503, 2001. (Pubitemid 33139873)
35. Gatzemeier U, Heckmayr M, Neuhauss R et al: Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer 12(Suppl 2): S101-106, 1995.
36. Socinski MA, Sandler AB, Israel VK et al: Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated stage IIIB/IV non-small cell lung carcinoma. Cancer 95: 1520-1527, 2002.